Which inhaler would be most appropriate for a COPD patient requiring regular maintenance therapy with normal eosinophil count and no asthma features?

• A. Salmeterol
• B. Anoro (umeclidinium / vilanterol)
• C. Fluticasone inhaler
• D. Tiotropium alone

Answer: (B)

Regular maintenance in COPD is best achieved with bronchodilators that work by different mechanisms to maximize and sustain airway dilation. When eosinophil count is normal and there are no asthma features, adding inhaled corticosteroids offers limited benefit and adds risk (such as pneumonia). A fixed-dose combination of umeclidinium (a long-acting muscarinic antagonist) and vilanterol (a long-acting beta-2 agonist) provides dual bronchodilation in one inhaler, typically offering greater symptom control and lung function improvement than either component alone. So, umeclidinium/vilanterol is the most appropriate maintenance option here.

Salmeterol alone is helpful but may be less effective than the LAMA/LABA combo for ongoing maintenance. Tiotropium alone is beneficial but does not provide the extra bronchodilatory boost from a LABA. A fluticasone inhaler (steroid) is less suitable given the normal eosinophil count and absence of asthma features, due to lower expected benefit and potential adverse effects.